Wegovy 0.5mg: the second step in your titration schedule

The myth worth clearing up first: 0.5mg is not a treatment dose

A common misreading of the Wegovy schedule is that each dose level is doing its own job therapeutically, that 0.25mg offers a little weight loss, 0.5mg a bit more, and so on. That is not quite right. The lower doses in the semaglutide titration exist primarily to let your body adjust to the medicine, reducing the chance that nausea or gastrointestinal discomfort becomes overwhelming early on.

At 0.5mg, your prescriber is watching for tolerability, not expecting significant weight loss to show up on the scales. The NHS patient information for semaglutide confirms that the full maintenance dose is 2.4mg weekly, reached gradually after several months of titration. Meaningful average weight reduction in the STEP 1 clinical trial (around 15% of body weight over 68 weeks) was achieved at the 2.4mg maintenance level, not at the early dose steps.

So if you are currently at 0.5mg and wondering why the changes feel subtle, that is by design. The schedule is protecting you, not stalling you. You can read more about how the full titration works on our Wegovy doses overview.

What actually happens during the 0.5mg month

After four weeks at 0.25mg, your prescriber will typically move you to 0.5mg for a further four weeks, provided the lower dose was tolerated. This is one of the steps where some people notice a modest reduction in appetite for the first time, semaglutide's GLP-1 receptor activity slows gastric emptying and influences appetite signalling in the brain, and both effects become more perceptible as the dose rises.

Side effects may increase slightly compared with 0.25mg. Nausea, an unsettled stomach and softer stools are the most reported. These generally peak in the first week or two of each new dose level and then ease. If they do not ease, or if you experience severe or persistent abdominal pain that radiates to the back, contact a healthcare professional promptly, this is one of the symptoms associated with pancreatitis, which is a known but uncommon side effect of GLP-1 medicines, as flagged in MHRA safety guidance.

Questions about the relationship between the 0.5mg injection volume and what that means for the Wegovy 0.5 ml dose come up often; our page on the Wegovy 0.5mg pen covers the device detail in full.

Moving from 0.25mg to 0.5mg: what changes and what stays the same

The injection technique, site rotation (abdomen, thigh or upper arm) and weekly schedule do not change between doses. What changes is the amount of semaglutide delivered per injection. For most people the practical experience of injecting 0.5mg feels identical to 0.25mg, same pen mechanics, same aftercare.

If you started at 0.25mg and have been given the go-ahead to increase, our guide to moving from 0.25mg to 0.5mg walks through what the change involves clinically. And if you are weighing up whether 0.25mg and 0.5mg actually differ meaningfully in practice, the 0.25mg versus 0.5mg comparison covers that directly.

Storage remains the same throughout: Wegovy pens are kept refrigerated. For exact storage windows and the full list of instructions, your Patient Information Leaflet is the authoritative source, or the Wegovy SmPC on the eMC.

It is also worth being aware that the UK now has a higher-dose option. The MHRA approved a dedicated 7.2mg weekly pen in April 2026 for adults with a BMI of 30 or above, extending the ceiling beyond the previous 2.4mg maintenance dose for eligible patients. That approval does not change the titration steps lower in the schedule, but it does signal how the medicine is continuing to develop. More context on the full picture, including private treatment costs, is on our Wegovy price comparison page.

What comes next after 0.5mg

After four weeks at 0.5mg your prescriber reviews your tolerance and progress. If 0.5mg has been well tolerated, the next step is 1.0mg for a further four weeks, then 1.7mg, then the 2.4mg maintenance dose. NICE guidance (TA875) recommends considering stopping treatment if less than 5% weight loss has occurred after six months at the maintenance dose, your prescriber will have that in view throughout.

People who move through early dose steps quickly sometimes feel frustrated that titration takes months. The reasoning is straightforward: reaching a maintenance dose that works is far better than arriving there too fast and stopping because of side effects. Slower is often more effective in the long run.

Wegovy is a prescription-only medicine. If you have not yet started treatment and want to understand whether you are eligible, a free consultation with our prescribers is the right starting point, a real clinician reviews every submission and will discuss your full clinical picture before anything is prescribed.